An investment vehicle of a world-class CDMO partner from concept to commercialization is looking for partnerships with cell and gene therapy related pipelines companies in Pre-Seed or Series A rounds with typical check sizes ranging from $500k-2M USD. The fund is open to global companies though prefers US-based companies.
The firm is solely interested in cell and gene therapy related pipeline companies. The fund is indication-agnostic and is open to orphan diseases as well. Companies should be pre-IND and must have proof of concept.
The firm may take a board or observer seat on a case-by-case basis. The fund requires founders to be full-time.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Crafting a compelling tagline is more challenging than you would expect – many startups approach it based on what they think sounds good and come out with a slogan that does not give much information on the company. A tagline should give investors a noticeably clear idea of what your company is doing in just 5-7 words. This forms the foundation of a company’s marketing collateral, something we emphasize in our educational content and webinars. It is where we start with the companies we work with, helping them refine their message into a concise, compelling snapshot of the company. It often takes at least 20 versions and edits to land on a good tagline. Gauge your success by sharing it with people unfamiliar with your company – can they accurately describe what your technology is, and what problem/disease you are addressing? If not, go back to the drawing board, or ask for our help!
Next Phase Newsletter 